The advent of site specific/targeted drug delivery has revolutionized the drug delivery industry. This technique is allowing a previously unattainable level of drug delivery with greater efficiency to target organs and tissues. Due to this ability, the share of site specific drug delivery is incessantly increasing in the drug delivery industry. It is anticipated that the global site specific drug delivery market will cross US$ 114 Billion by 2022. The growth of the market is likely to be driven by expanding drug discovery applications, rising chronic disease incidences, and increasing research related activities for exploring drug delivery therapeutic applications. The report, "Site-Specific Drug Delivery Market, By Application (Pulmonary, Ocular, Oncology, CNS, Cardiovascular) - World Forecasts to 2022", provides an insight into the current and future prospective of this market. This report covers the major opportunities in this area, and drivers that have impact on the market. The report also discusses some of the challenges currently faced by the market. The major application areas of targeted drug delivery pulmonary, ocular, oncology, and others including CNS, cardiovascular, etc. Oncology based application is the largest area of application of targeted drug delivery. This large share can be attributed to various research related activities conducted for developing targeted drug delivery approach for cancer. Moreover, the report also contains the market share of major regions, including North America, Europe, and Asia Pacific. North America holds the largest market share, while Asia Pacific is expected to witness highest growth in the coming years, i.e. 2016-2022. The major reasons for the high growth are the ongoing researches in China and Australia, which is expanding therapeutic applications of site specific drug delivery to brain disorders. North America and Europe are expected to grow at a modest rate due to less stringent regulatory approval process and advancements in drug delivery technique. The last segment of the report is entirely devoted to profiling leading companies of the targeted drug delivery industry, including some major players like Celgene Corporation, Arrowhead Pharma, Intezyne, Endocyte, BioDelivery Sciences International, PharmaIN, Mirus Bio, Savara, etc. This segment provides access to the financials, product portfolio, and recent developments of these companies. This segment also discusses the strengths and weaknesses of key players in this industry. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global site specific drug delivery market.
Table of Contents
1. Analyst View 2. Research Methodology 3. Introduction to Site-Specific Drug Delivery 4. Market Dynamics 4.1 Market Drivers 4.1.1 Increasing Complexity of Drug Molecules 4.1.2 Need for Improved Site-Specific Drug Delivery 4.1.3 Advent of Nanotechnology in Site-Specific Drug Delivery 4.1.4 Increasing Investments 4.2 Market Restraints 4.2.1 Complexity in Biopharma Supply Chain & Operations 4.2.2 Issues in Quality Compliance & Regulatory Screening 4.3 Market Opportunities 4.3.1 Increasing R&D Spending in Site-Specific Drug Delivery Technologies 4.3.2 Surging Demand for In-Licensing Drug Delivery Products & Technologies 5. Global Site-Specific Drug Delivery Market Outlook to 2022 6. Site-Specific Drug Delivery Market by Application 6.1 Pulmonary 6.2 Ocular 6.3 Oncology 6.4 Others 7. Site-Specific Drug Delivery Market by Geography 7.1 North America 7.2 Europe 7.3 Asia Pacific 8. Trends & Developments 8.1 Nanotechnology Application for Brain Drug Delivery 8.2 Nanosized Drug Carriers for Ocular Drug Delivery 8.3 Nanotechnology Mediated Site-Specific Drug Delivery for Cancer 9. Mergers, Acquisitions, & Collaborations 10. Company Profiles 10.1 Celgene Corporation 10.2 Arrowhead Pharmaceuticals, Inc. 10.3 BioDelivery Sciences International, Inc. 10.4 Endocyte, Inc. 10.5 Intezyne, Inc. 10.6 PharmaIN 10.7 Kurve Technology, Inc. 10.8 Mirus Bio LLC. 10.9 Savara Inc. 10.10 Delpor, Inc.
List of Tables: Table 12-1: Celgene Corporation - Product Portfolio Table 12-2: Celgene Corporation - Product Pipeline Table 12-3: Celgene Corporation - Key Financials (Million US$), 2013-2015 Table 12-4: Arrowhead Pharmaceuticals, Inc. - Product Pipeline Table 12-5: Arrowhead Pharmaceuticals, Inc. - Key Financials (Million US$), 2013-2015 Table 12-6: BioDelivery Sciences International, Inc. - Product Portfolio Table 12-7: BioDelivery Sciences International, Inc. - Product Pipeline Table 12-8: BioDelivery Sciences International, Inc. - Key Financials (Million US$), 2012-2014 Table 12-9: Endocyte, Inc. - Technology Portfolio Table 12-10: Endocyte, Inc. - Product Pipeline Table 12-11: Endocyte, Inc. - Key Financials (Million US$), 2013-2015 Table 12-12: Intezyne, Inc. - Product Pipeline Table 12-13: PharmaIN - Technology Portfolio Table 12-14: PharmaIN - Product Pipeline Table 12-15: Kurve Technology, Inc. - Product & Technology Portfolio Table 12-16: Mirus Bio LLC. - Product & Service Portfolio Table 12-17: Savara Inc. - Product Portfolio Table 12-18: Savara Inc. - Product Pipeline Table 12-19: Delpor, Inc. - Product & Technology Portfolio Table 12-20: Delpor, Inc. - Product Pipeline
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.